Vaccine Experience
The world of vaccine development and manufacturing requires rigorous attention to quality and safety and focus on increased speed to market and reduced cost of goods. This has only intensified during the COVID-19 pandemic. We bring over a decade of consistent experience with leaders in vaccines, including Sanofi Pasteur, Merck, GSK, and Pfizer. In response to the H1N1 swine flu pandemic, we partnered with Sanofi Pasteur in Swiftwater, PA for their egg-based flu vaccine and Novartis in Holly Springs, NC on the first facility in the US to manufacture vaccines using cell culture technology. The Holly Springs facility is built for pandemic avian flu and is prepared to a manufacture pandemic flu vaccine if required. Our long-term experience in the design, construction and validation of vaccine, API, and antibody therapy facilities is comprehensive and second to none.
The Holly Springs facility is built for pandemic avian flu and is prepared to a manufacture pandemic flu vaccine if required. Our long-term experience in the design, construction and validation of vaccine, API, and antibody therapy facilities is comprehensive and second to none.
As a result of COVID-19, we saw an increase in government funding for R&D for COVID-19 vaccines and palliative treatments. Since the beginning of the pandemic, we have provided fast-track EPCM services for numerous retrofit and scale up projects including AstraZeneca’s vaccine manufacturing facility in West Chester, OH. As countries around the world begin investing in domestic vaccine manufacturing capabilities, our experience and global market knowledge position us to provide valuable solutions with a focus on safety and speed.
Novartis | US Flu Cell Culture Facility (USFCC) | Holly Springs, NC
Flexible Design
We deliver with the end in mind, helping our clients by designing flexible facilities that allow our clients to increase capacity due to market demand. We designed / built the factories of the future that are intended for global multi-site deployment, to be able to quickly ramp up production due to pandemic situations. For Amgen’s Manufacturing of the Future facility in Singapore, we utilized our best in class Solutions and Technology team to design a facility capable of producing mammalian protein based commercial drug substance products through a lean manufacturing approach that is more versatile and efficient than traditional production facilities.
Innovation and Technology
Our Subject Matter Experts are leaders in bulk biologics, API, and fill finish technologies. Our innovative design includes facilities for mAb, Mammalian Cell Culture, Microbial Fermentation, large scale cell culture and vaccine manufacturing. We design facilities for multiple large-scale bioreactors, single use bioreactors and hybrid of both – all based on developing a solution for our client’s specific project needs. We work with clients in developing commercialization techniques for large- and small-scale API applying advanced analytics, P.A.T., and continuous manufacturing technologies. We are currently executing fill/finish projects with a requirement for a high level of flexibility, to produce multiple products in vials and syringes. We are also working with our clients to develop facilities to produce high volumes of vaccines at fixed low cost of goods. We work with and challenge equipment vendors to develop new approaches for using existing technologies for different unit operations.
Medical Device Products
The immediate need for COVID-19 testing kits has grown immensely. We have worked with some of the leaders in medical device products, including Siemens, GSK, and AstraZeneca. For Siemens, we provided design and construction services for a new 120,000 SF facility for the large-scale manufacturing of Immunoassay Reagent Test Kits. This facility was originally designed for flexibility, and due to the demand of test kits, we recently partnered with Siemens for the expansion of this site to increase capacity.
Jacobs leads the global professional services sector providing solutions for a more connected, sustainable world. jacobs.com